Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742161 | 1.00 | TSHR (0.47) | TSHRMAPK1MAPTGFERPIM3 | |
| SCHEMBL2250758 | 0.90 | TSHR (0.47) | TSHRMAPK1MAPTGFERPIM3 | |
| SCHEMBL27747270 | 0.86 | PARP1 (0.50) | MAPTPARP1LMNAMEN1KMT2A | |
| SCHEMBL2244805 | 0.84 | TDP1 (0.45) | TSHRMAPTPARP1LMNAMEN1 | |
| SCHEMBL358123 | 0.84 | EGFR (0.42) | TSHRMAPK1MAPTPIM3PIM1 | |
| SCHEMBL2597703 | 0.84 | PARP1 (0.40) | TSHRMAPK1MAPTPIM1PARP1 | |
| SCHEMBL8195276 | 0.84 | MEN1 (0.38) | TSHRMAPK1MAPTPARP1LMNA | |
| SCHEMBL1024702 | 0.84 | MAPT (0.47) | TSHRMAPTPARP1LMNAMEN1 | |
| SCHEMBL28027642 | 0.84 | MEN1 (0.38) | TSHRMAPK1MAPTPARP1LMNA | |
| SCHEMBL404980 | 0.84 | TSHR (0.45) | TSHRMAPK1MAPTGFERPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250066356-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220238-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3592741-B1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-111201226-B | Cyclic substituted imidazo [4,5-c ] quinoline derivatives | 辉瑞大药厂 | 2022-07-22 | — | — | CN | disclosed |
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3592740-B1 | CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | PFIZER (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210355117-A1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-11-18 | — | — | US | disclosed |
| US-11161844-B2 | Cyclic substituted imidazo[4,5-c]quinoline derivatives | PFIZER INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-2324029-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2011001212-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-01-06 | — | — | WO | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| EP-1509521-B1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-11-03 | — | — | US | disclosed |
| EP-1509521-A2 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097641-A2 | 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | ABL1, PRKCA, PRKCQ | TSHR 3046/4885MAPK1 251/4885MAPT 1405/4885 |
| US-20250066356-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | TSHR 4664/4885MAPK1 93/4885MAPT 14/4885 |
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | LRRK2, PARK7, BRCA1 | TSHR 3356/4885MAPK1 196/4885MAPT 106/4885 |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | TSHR 82/4885MAPK1 2185/4885MAPT 2336/4885 |
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | TSHR 4664/4885MAPK1 93/4885MAPT 14/4885 |
| US-11161844-B2 | Cyclic substituted imidazo[4,5-c]quinoline derivatives | LRRK2, PARK7, BRCA1 | TSHR 2171/4885MAPK1 573/4885MAPT 197/4885 |
| US-20210355117-A1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | LRRK2, PARK7, BRCA1 | TSHR 3498/4885MAPK1 159/4885MAPT 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.